APA (7th ed.) Citation

C, B., R, M., EM, S., F, M., R, R., A, C., . . . SW, L. (2025). A RAS(ON) Multi-Selective Inhibitor Combination Therapy Triggers Long-term Tumor Control through Senescence-Associated Tumor-Immune Equilibrium in Pancreatic Ductal Adenocarcinoma. Cancer discovery, 15(8), 1717. https://doi.org/10.1158/2159-8290.CD-24-1425

Chicago Style (17th ed.) Citation

C, Broderick, et al. "A RAS(ON) Multi-Selective Inhibitor Combination Therapy Triggers Long-term Tumor Control Through Senescence-Associated Tumor-Immune Equilibrium in Pancreatic Ductal Adenocarcinoma." Cancer Discovery 15, no. 8 (2025): 1717. https://doi.org/10.1158/2159-8290.CD-24-1425.

MLA (9th ed.) Citation

C, Broderick, et al. "A RAS(ON) Multi-Selective Inhibitor Combination Therapy Triggers Long-term Tumor Control Through Senescence-Associated Tumor-Immune Equilibrium in Pancreatic Ductal Adenocarcinoma." Cancer Discovery, vol. 15, no. 8, 2025, p. 1717, https://doi.org/10.1158/2159-8290.CD-24-1425.